Human Patient-Derived Kidney Cancer Organoid is a 3D cancer organoid model established from resected kidney tumor tissue. Derived from patient tumor cells, including native cancer stem cell populations, this organoid retains the histological architecture, genetic mutations, and molecular features of the original tumor. It can be maintained long-term in vitro and replicates tumor heterogeneity. Unlike traditional 2D cancer cell lines, this organoid model offers enhanced fidelity for modeling disease progression and predicting patient-specific therapeutic responses in renal cancer research. Organoids undergo rigorous testing for mycoplasma, bacteria, fungi/yeast, and are verified for identity, genetic stability, and functional performance.
Embedded 3D Culture
All test negative for mycoplasma, bacteria, yeast, and fungi.
For research use only. Kidney cancer organoid is a powerful tool for translational oncology, supporting drug screening, resistance mechanism analysis, biomarker identification, and personalized medicine. It enables preclinical testing of targeted therapies, immunotherapies, and combination treatments under physiologically relevant conditions. The model can be co-cultured with immune or stromal cells to simulate the tumor microenvironment, making it ideal for investigating tumor-immune interactions and optimizing next-generation treatment strategies for renal cancer.
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.